U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07116057) titled 'MOv19-BBz CAR T Cells in FRa+ Cancers' on Aug. 04.
Brief Summary: This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only. Subjects will receive a single dose of MOv19-BBz CAR T cells via intrapleural infusion following lymphodepleting chemotherapy. Subjects without an existing intra-pleural catheter will have a temporary pleural catheter placed for the study. Subjects may initiate treatment ...